Low prevalence of renal, cardiac, pulmonary, and neurological extra-articular clinical manifestations in spondyloarthritis: analysis of the Brazilian Registry of Spondyloarthritis by Rodrigues, Carlos Ewerton Maia et al.
ORIGINAL ARTICLE
375Rev Bras Reumatol 2012;52(3):375-383
Received on 10/24/2011. Approved on 03/05/2012. Percival Sampaio-Barros declares to have received a research grant from Federico Foundation. The other 
authors declare no confl ict of interest. Financial Support: The electronic version of the Brazilian Registry of Spondyloarthritis is supported by a donation from 
the Wyeth/Pfi zer Brasil, which has infl uence on neither data collection and analysis, nor article writing and publishing.
Registro Brasileiro de Espondiloartrites.
The author's institutions are listed at the end of this article.
Correspondence to: Dr. Carlos Ewerton Maia Rodrigues. Serviço de Reumatologia, Hospital Geral de Fortaleza. Rua Ávila Goulart, 900 – Papicu. CEP: 60175-295.
Fortaleza, CE, Brasil. E-mail: carlosewerton@hotmail.com
Low prevalence of renal, cardiac, pulmonary, 
and neurological extra-articular clinical 
manifestations in spondyloarthritis: analysis of 
the Brazilian Registry of Spondyloarthritis 
Carlos Ewerton Maia Rodrigues1, Walber Pinto Vieira2, Adriana B. Bortoluzzo3, Célio Roberto Gonçalves4, 
José Antonio Braga da Silva5, Antonio Carlos Ximenes6, Manoel B. Bértolo7, Sandra L. E. Ribeiro8, 
Mauro Keiserman9, Rita Menin10, Thelma L. Skare11, Sueli Carneiro12, Valderílio F. Azevedo13, Elisa N. Albuquerque14, 
Washington A. Bianchi15, Rubens Bonfi glioli16, Cristiano Campanholo17, Hellen M. S. Carvalho18, Izaias P. Costa19, 
Angela P. Duarte20, Charles L. Kohem21, Nocy H. Leite22, Sonia A. L. Lima23, Eduardo S. Meirelles24, 
Ivânio A. Pereira25, Marcelo M. Pinheiro26, Elizandra Polito27, Gustavo G. Resende28, Francisco Airton C. Rocha29, 
Mittermayer B. Santiago30, Maria de Fátima L. C. Sauma31, Valeria Valim32, Percival D. Sampaio-Barros33
ABSTRACT
Objective: To describe the extra-articular manifestations (cardiac, renal, pulmonary, and neurological), usually not 
related to spondyloarthritis (SpA), in a large cohort of Brazilian patients. Materials and methods: This retrospective 
study analyzed 1,472 patients diagnosed with SpA and cared for at 29 health care centers distributed in the fi ve major 
geographic regions in the country, participating in the Brazilian Registry of Spondyloarthritis (BRS). All patients were 
assessed for the prevalence of major extra-articular manifestations (cardiac, renal, pulmonary, and neurological), clas-
sifi ed according to the diagnosis [ankylosing spondylitis (AS), psoriatic arthritis (PsA), reactive arthritis (ReA), arthritis 
associated with infl ammatory bowel disease (IBD), undifferentiated spondyloarthritis (uSpA), and juvenile SpA], and 
according to the clinical presentation (axial, peripheral, mixed, and enthesitis). Results: Of the patients with SpA as-
sessed, 963 had AS, 271 PsA, 49 ReA, 48 arthritis associated with IBD, 98 uSpA, and 43 juvenile SpA. Cardiac involve-
ment was reported in 44 patients (3.0%), pulmonary involvement in 19 (1.3%), renal involvement in 17 (1.2%), and 
neurological involvement in 13 patients (0.9%). Most patients with visceral involvement had AS or PsA, and the mixed 
(axial + peripheral) and/or predominantly axial clinical form. Conclusion: Cardiac, renal, pulmonary, and neurological 
extra-articular manifestations are quite infrequent in SpA, ranging from 0.9% to 3% in this large Brazilian cohort, and 
affected predominantly patients with AS and PsA.
Palavras-chave: spondylitis, neurology, cardiology, pulmonary medicine, nephrology.
© 2012 Elsevier Editora Ltda. All rights reserved.
INTRODUCTION
The spondyloarthritis (SpAs) comprise a set of rheumatic 
diseases of immune origin and familial pattern, having some 
characteristics in common, such as infl ammatory axial pain, 
peripheral arthritis, enthesitis, and uveitis associated with 
sacroiliitis in genetically predisposed individuals (related to 
the human histocompatibility antigen HLA-B27).1 That set 
of diseases includes ankylosing spondylitis (AS), psoriatic 
arthritis (PsA), reactive arthritis (ReA), arthritis associated 
with infl ammatory bowel disease (IBD), and undifferentiated 
spondyloarthritis (uSpA). 
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Table 1
Extra-articular manifestations in spondyloarthritis
Extra-articular 
manifestations Clinical manifestations
Cardiac Aortitis; aortic insuffi ciency; conduction disorders; bundle- 
branch and atrioventricular blocks
Renal Secondary amyloidosis; IgA nephropathy 
Pulmonary Fibrosis of the upper lobe and pleural thickening
Neurological Cauda equina syndrome
In that broad context, other organic systems can be in-
volved. All conditions and symptoms not directly related to 
the articular system are considered extra-articular manifesta-
tions.2 Such manifestations can be divided into two groups 
as follows: those related to the concept of SpA, such as the 
involvement of the skin, eye, bowel or urogenital system; and 
those refl ecting a long-term chronic infl ammatory process, 
involving the lungs, heart, kidneys, and nervous system.2 
The manifestations related to SpA are relatively frequent 
(20%–60%),3 can occur at any time of disease progression, 
and sometimes can be related to the axial and peripheral 
infl ammatory process. On the other hand, the renal, cardiac, 
pulmonary and neurological manifestations are very rare 
(1%–5%), frequently subclinical, occurring usually in asso-
ciation with long-term disease and not related to the articular 
manifestations.2 
This study aimed at describing the prevalence of the extra-
articular manifestations of SpA in Brazilian patients from 
a national databank, comprising the Brazilian’s major tertiary 
health care centers, focusing on the renal, pulmonary, cardiac 
and neurological manifestations. 
MATERIALS AND METHODS
This is a cross-sectional descriptive study developed at sev-
eral tertiary health care centers in Brazil participating in the 
Brazilian Registry of Spondyloarthritis (BRS), representing the 
fi ve Brazilian geographic macroregions, with patients cared for 
from January 2006 to December 2009. A common protocol of 
investigation was applied to 1,472 consecutive patients diag-
nosed with SpA. The diagnosis of SpA was considered when 
the patients met the modifi ed New York criteria.4 Psoriatic 
arthritis was considered when the patients met the Moll and 
Wright criteria.5 The diagnosis of ReA was considered when 
asymmetric infl ammatory oligoarthritis of the lower limbs was 
associated with enthesopathy and/or infl ammatory low back 
pain after enteric and/or urogenital infections.6 Arthritis associ-
ated with IBD was considered in the presence of infl ammatory 
axial pain and/or peripheral articular involvement associated 
with IBD (Crohn disease or ulcerative colitis).7 Juvenile SpA 
was considered when the SpA symptoms began before the 
age of 16 years.7
The patients were assessed for the following: prevalence of 
the major extra-articular manifestations (cardiac, pulmonary, 
renal, and neurological), which are shown in Table 1; clinical 
diagnoses (AS, PsA, ReA, arthritis associated with IBD, uSpA, 




Of 1,472 patients diagnosed with SpA, 44 (3%) had cardiac 
involvement, mainly conduction disorders and bundle-branch 
blocks. Regarding the clinical diagnosis, cardiac involve-
ment was more frequent in AS and PsA and no patient with 
arthritis associated with IBD was diagnosed with cardiac 
involvement (Table 2). Regarding the clinical forms, cardiac 
involvement was more frequently found in the mixed and 
axial forms (Table 3). 
Pulmonary involvement
Pulmonary involvement was reported by 19 patients (1.3%), 
who had pulmonary fi brosis (apical and/or unspecifi c fi ndings) 
and pleural thickening. Pulmonary changes clearly predomi-
nated in patients with AS (Table 2). Regarding the clinical 
forms, pulmonary involvement was more frequently found in 
the mixed and axial forms (Table 3). 
Renal involvement
Renal involvement was identifi ed in 17 patients (1.2%), some 
of whom were diagnosed with IgA nephropathy, while the 
others had chronic hematuria with no diagnostic elucidation. 
Among the patients with renal involvement, AS and PsA 
predominated (Table 2). Regarding the clinical forms, renal 
involvement was more frequently found in the mixed form 
(Table 3). 
Neurological involvement
Thirteen patients (0.9%) had neurological involvement, 
mainly paresthesia of their lower limbs, which hindered de-
ambulation. Five patients had the diagnosis of cauda equina 
syndrome confi rmed. Among the patients with neurological 
involvement, AS (Table 2) and the mixed clinical form (Table 3) 
predominated.
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Table 3
Prevalence of the extra-articular manifestations of spondylo-
arthritis according to the clinical form
Extra-articular 
manifestations
Clinical form of spondyloarthritis (n = 1,472)
Axial Peripheral Mixed Enthesitic
Cardiac (n = 44) 12 (0.8%) 6 (0.4%) 25 (1.7%) 1 (0.1%)
Renal (n = 17) 2 (0.1%) 2 (0.1%) 13 (0.9%) 0
Pulmonary (n = 19) 9 (0.7%) 0 10 (0.7%) 0
Neurological (n = 13) 2 (0.1%) 2 (0.1%) 9 (0.5%) 0
Table 2
Prevalence of the extra-articular manifestations in spondylo-













Primary AS 29 (2%) 5 (0.3%) 14 (1.0%) 8 (0.5%)
AS + psoriasis 1 (0.1%) 1 (0.1%) 0 0
PsA 11 (0.7%) 6 (0.4%) 1 (0.1%) 3 (0.2%)
ReA 1 (0.1%) 1 (0.1%) 1 (0.1%) 0
uSpA 1 (0.1%) 0 1 (0.1%) 0
AS + IBD 0 0 1 (0.1%) 0
Arthritis + IBD 0 1 (0.1%) 0 1 (0.1%)
Juvenile SpA 1 (0.1%) 3 (0.2%) 1 (0.1%) 1 (0.1%)
AS: ankylosing spondylitis; PsA: psoriatic arthritis; ReA: reactive arthritis; uSpA: undifferentiated 
spondyloarthritis; IBD: infl ammatory bowel disease; juvenile SpA: juvenile spondyloarthritis.
DISCUSSION 
This is the fi rst study describing the major extra-articular 
manifestations (cardiac, renal, neurological, and pulmonary) 
of SpA in a large number of Brazilian patients, representing 
all the fi ve major geographic regions of the country. Systemic 
extra-articular manifestations, although rare, have high mor-
bidity and, thus, should be diagnosed and treated early.
Cardiac symptoms in patients with AS are rarely reported; 
cardiac diseases occur in 2%–10% of those patients, mainly 
in those with long-term disease, and are not associated with 
joint disease activity.2 HLA-B27 positive individuals can have 
a syndrome characterized by aortic insuffi ciency (with isolated 
regurgitation and no stenosis) associated with aortic root di-
lation and fi brosis with retraction of the cusps, which could 
progress to complete atrioventricular block and endarteritis 
obliterans of the small arteries.8 Third-degree atrioventricular 
block requiring the use of pacemaker and with no defi ned cause 
in young men seems to be associated with a higher preva-
lence of HLA-B27,9 and can even be considered an uSpA.10 
Currently, the occurrence of aortic insuffi ciency in SpA is not 
frequent,11,12 in accordance with the clinical fi ndings of the 
present study. In this Brazilian cohort, cardiac involvement was 
observed in 3% of the 1,472 patients assessed, predominating 
in those with AS and PsA, with the mixed clinical form, fol-
lowed by the axial form.
 In recent years, both AS and PsA seem to be associated 
with an increase in cardiovascular morbidity and mortality.13,14 
An extensive study assessing 28,208 patients with rheumatoid 
arthritis (RA), 3,066 patients with PsA, and 1,843 with AS, and 
comparing them with the healthy North-American population 
has revealed that both the cardiovascular diseases and their risk 
factors are more frequent in RA, PsA, and AS as compared with 
the paired control group.15 That Brazilian study has not assessed 
actively the occurrence of metabolic syndrome in patients with 
SpA, which can be studied in the second phase of the BRS.
Pulmonary involvement in AS is unusual and estimated to 
occur in less than 1% of the patients, especially in severe long-
term disease.16 We observed 1.3% of pulmonary involvement 
in patients with SpA, with predominance of unspecifi c fi brotic 
changes in the high-resolution computed tomography of pa-
tients with AS. Tomographic studies, usually in patients with 
AS, have also reported unspecifi c tomographic changes.17–19 
Usually such changes have no direct relationship with disease 
progression. Involvement of the costovertebral joints and 
ankylosis of the thoracic vertebral column will lead to limita-
tion of the thoracic expansion, which can affect the patient’s 
respiratory capacity, but rarely leads to restrictive respiratory 
disorder, because the diaphragmatic function is preserved.2
The symptomatic renal involvement is usually rare in pa-
tients with SpA. IgA nephropathy has been described in spon-
dylitic patients for decades, being characterized by hematuria 
and proteinuria (usually mild), with mesangial IgA deposits on 
the renal biopsy, and no poor prognosis.20 The most frequent 
fi nding of the renal involvement in SpA is hematuria, usually 
microscopic; in such cases, in addition to IgA nephropathy, 
interstitial nephropathy due to non-steroidal anti-infl amma-
tory drugs or renal lithiasis should be considered.21–23 In this 
Brazilian multicenter study, only 1.2% of the patients had renal 
involvement, mainly chronic hematuria with no specifi c cause. 
A recent Brazilian study has reported intermittent microscopic 
hematuria in 44.7% of 76 spondylitic patients, of whom only 
10.5% could have a glomerular etiology.24 
Renal amyloidosis, not described in this cohort and very 
rarely described in Latin-American case series,25 is usually 
more often reported in European patients with SpA. Renal 
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amyloidosis was the cause of death in 13% of the spondy-
litic patients of a Finnish case series followed up for a long 
time.26 A Spanish study using the method of abdominal fat 
aspiration has found amyloidosis in 7% of the 107 patients 
assessed.27
The neurological involvement in SpA is a clinical mani-
festation found almost exclusively in AS. In our cohort, of the 
13 patients with neurological manifestations, eight had AS. 
The neurological changes more often reported in the literature 
are atlantoaxial subluxation and cauda equina syndrome.28,29 
A recent literature review assessing the evolution of the 
neurological complications after vertebral column fracture has 
revealed a 17.7% mortality after three months.30
In conclusion, extra-articular manifestations (cardiac, renal, 
pulmonary, and neurological) are extremely rare in Brazilian 
patients with SpA, ranging from 0.9%–3%, being, thus, in 
accordance with data in the literature.1 Such manifestations 
should be considered in patients with refractory long-term 
disease. Their diagnosis requires strong clinical suspicion, 
because the symptoms are unspecifi c and often subclinical. 
Initial check-up and regular control of such manifestations 
should, thus, be part of those patients’ follow-up.
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